These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 33537013)
1. Considerations for Phage Therapy Against Senhaji-Kacha A; Esteban J; Garcia-Quintanilla M Front Microbiol; 2020; 11():609017. PubMed ID: 33537013 [TBL] [Abstract][Full Text] [Related]
2. Mycobacterium abscessus Strain Morphotype Determines Phage Susceptibility, the Repertoire of Therapeutically Useful Phages, and Phage Resistance. Dedrick RM; Smith BE; Garlena RA; Russell DA; Aull HG; Mahalingam V; Divens AM; Guerrero-Bustamante CA; Zack KM; Abad L; Gauthier CH; Jacobs-Sera D; Hatfull GF mBio; 2021 Mar; 12(2):. PubMed ID: 33785625 [No Abstract] [Full Text] [Related]
3. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Nick JA; Dedrick RM; Gray AL; Vladar EK; Smith BE; Freeman KG; Malcolm KC; Epperson LE; Hasan NA; Hendrix J; Callahan K; Walton K; Vestal B; Wheeler E; Rysavy NM; Poch K; Caceres S; Lovell VK; Hisert KB; de Moura VC; Chatterjee D; De P; Weakly N; Martiniano SL; Lynch DA; Daley CL; Strong M; Jia F; Hatfull GF; Davidson RM Cell; 2022 May; 185(11):1860-1874.e12. PubMed ID: 35568033 [TBL] [Abstract][Full Text] [Related]
4. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. Dedrick RM; Smith BE; Cristinziano M; Freeman KG; Jacobs-Sera D; Belessis Y; Whitney Brown A; Cohen KA; Davidson RM; van Duin D; Gainey A; Garcia CB; Robert George CR; Haidar G; Ip W; Iredell J; Khatami A; Little JS; Malmivaara K; McMullan BJ; Michalik DE; Moscatelli A; Nick JA; Tupayachi Ortiz MG; Polenakovik HM; Robinson PD; Skurnik M; Solomon DA; Soothill J; Spencer H; Wark P; Worth A; Schooley RT; Benson CA; Hatfull GF Clin Infect Dis; 2023 Jan; 76(1):103-112. PubMed ID: 35676823 [TBL] [Abstract][Full Text] [Related]
5. Phage Therapy for Mycobacterium Abscessus and Strategies to Improve Outcomes. Hashemi Shahraki A; Mirsaeidi M Microorganisms; 2021 Mar; 9(3):. PubMed ID: 33799414 [TBL] [Abstract][Full Text] [Related]
6. Bacteriophage infection and killing of intracellular Schmalstig AA; Wiggins A; Badillo D; Wetzel KS; Hatfull GF; Braunstein M mBio; 2024 Jan; 15(1):e0292423. PubMed ID: 38059609 [TBL] [Abstract][Full Text] [Related]
7. Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Rossitto M; Fiscarelli EV; Rosati P Front Microbiol; 2018; 9():775. PubMed ID: 29780361 [TBL] [Abstract][Full Text] [Related]
8. Understanding the Phage-Host Interaction Mechanism toward Improving the Efficacy of Current Antibiotics in Gorzynski M; De Ville K; Week T; Jaramillo T; Danelishvili L Biomedicines; 2023 May; 11(5):. PubMed ID: 37239050 [TBL] [Abstract][Full Text] [Related]
9. Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus. Johansen MD; Alcaraz M; Dedrick RM; Roquet-Banères F; Hamela C; Hatfull GF; Kremer L Dis Model Mech; 2021 Sep; 14(9):. PubMed ID: 34530447 [TBL] [Abstract][Full Text] [Related]
18. Alternative and Experimental Therapies of Meir M; Barkan D Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32948001 [No Abstract] [Full Text] [Related]
19. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Dedrick RM; Freeman KG; Nguyen JA; Bahadirli-Talbott A; Smith BE; Wu AE; Ong AS; Lin CT; Ruppel LC; Parrish NM; Hatfull GF; Cohen KA Nat Med; 2021 Aug; 27(8):1357-1361. PubMed ID: 34239133 [TBL] [Abstract][Full Text] [Related]
20. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going? Luong T; Salabarria AC; Roach DR Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]